Get the Stockscreener App
32.60
3.01%
-1.01
After Hours:
32.62
0.02
+0.06%
Moderna Inc stock is traded at $32.60, with a volume of 9.47M.
It is down -3.01% in the last 24 hours and down -31.41% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$33.61
Open:
$33.51
24h Volume:
9.47M
Relative Volume:
0.93
Market Cap:
$12.58B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-5.6014
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
-17.30%
1M Performance:
-31.41%
6M Performance:
-60.02%
1Y Performance:
-67.17%
1-Day Range:
$32.46
$33.77
1-Week Range:
$32.46
$38.65
52-Week Range:
$31.94
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
32.60 | 12.58B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards? - Yahoo Finance
Moderna (NASDAQ:MRNA) Trading Down 4.7%Here's Why - MarketBeat
Robeco Institutional Asset Management B.V. Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Pacer Advisors Inc. Sells 20,901 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Spire Wealth Management Purchases 22,192 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
3 Top AI-Powered Biotech Stocks to Buy in February - The Motley Fool
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now? - AOL
Is Moderna Stock A Sell With Robert F. Kennedy Eyeing The Lead Role At HHS? - Yahoo! Voices
KBC Group NV Sells 38,943 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Do Wall Street Analysts Like Moderna Stock? - Nasdaq
Everett Harris & Co. CA Invests $275,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Why Moderna, Inc. (MRNA) Went Down on Tuesday - MSN
Why Moderna Inc. (MRNA) Crashed on Monday - MSN
Moderna call volume above normal and directionally bullish - TipRanks
Global mRNA Vaccines and Therapeutics Market is expected - openPR
Moderna and BioNTech shares fall after Senate committee vote RFK Jr. - Investing.com Canada
This Is What Whales Are Betting On Moderna - Benzinga
Swedbank AB Raises Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna reports record for UK clinical trials in 2023/24 -February 04, 2025 at 06:31 am EST - Marketscreener.com
Moderna reports record for UK clinical trials in 2023/24 - European Pharmaceutical Review
Moderna, Inc. (NASDAQ:MRNA) Receives $67.26 Consensus Target Price from Analysts - MarketBeat
Moderna secures EU deal for mRNA COVID-19 vaccine supply - MSN
U.S. Markets Closed Down Monday; Moderna Took Biggest Hit - Barron's
Moderna Options Trading: A Deep Dive into Market Sentiment - Benzinga
Moderna touts UK R&D and manufacturing progress - The Pharma Letter
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates? - Yahoo Finance
Moderna, Inc.'s (NASDAQ:MRNA) Business And Shares Still Trailing The Industry - Simply Wall St
MODERNA WAS THE LARGEST INDUSTRY SPONSOR OF CLINICAL TRIALS IN THE UK IN 2023/24 AS CONSTRUCTION ON MODERNA INNOVATION AND TECHNOLOGY CENTRE IN OXFORDSHIRE NEARS COMPLETION - PharmiWeb.com
Moderna: The Good News Isn't Enough (NASDAQ:MRNA) - Seeking Alpha
Objective long/short (MRNA) Report - Stock Traders Daily
Moderna (NASDAQ:MRNA) Shares Gap Down After Analyst Downgrade - MarketBeat
Discover Why Moderna's Stock Could Skyrocket in 2025! - Jomfruland.net
Why Are Analysts Bullish on Moderna, Inc. (MRNA) Now? - MSN
Exchange Traded Concepts LLC Has $1.09 Million Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Price Target Lowered to $99.00 at The Goldman Sachs Group - MarketBeat
Moderna Stock Price | MRNA Stock Quote, News, and History - Markets Insider
The Goldman Sachs Group Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
March 14th Options Now Available For Moderna (MRNA) - Nasdaq
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know - MSN
Why Moderna (MRNA) Crashed on Wednesday? - Yahoo Finance
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine - Pulmonology Advisor
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Analyst Downgrade - MSN
Decoding Moderna's Options Activity: What's the Big Picture? - Benzinga
Moderna Shares Fall After TD Cowen Cuts Price Target -January 29, 2025 at 02:55 pm EST - Marketscreener.com
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines - AOL
Why MRNA Stock Is Retreating - Yahoo Finance
Moderna Stock Is Sliding Wednesday: Here's Why - Benzinga
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):